Yuhan Stays Committed
to Producing Best
Pharmaceuticals

Develops Korea's first new medicine on the treatment of gastrointestinal ulcer

"We shall provide the best pharmaceutical products for the nation and the people"is one of the founding spirits cherished by Yuhan Corp.'s founder Dr. Ihan, New. Since its inception, Yuhan Corp. has been staying committed to making the production of best pharmaceuticals one of its foremost tasks by strengthening its R&D capabilities.
These efforts have paid off: the development of Revanex, Korea's first new medicine on the treatment of gastrointestinal ulcer, approved by the Korea Food and Drug Administration in September 2005. Revanex is a novel antisecretory agent with a new mode of action discovered and being developed by Yuhan Research Institute. Revanex presents a reversible mode of action against Acid Pump, the final mediator of acid secretion. Currently, Yuhan is finalizing Phase III study on Gastric Ulcer and Gastritis and Phase II study on GERD, FD and H. Pylori Eradication.In particular, in an effort to build up world-class R&D infrastructure together with an expansion of R&D space,investments and soupped-up manpower and network, the Yuhan Research Institute has bee relocated to Giheung,
Yongin City in August, 2005 in line with the completion of the nation's largest, cutting-edge research center.
Yuhan Corp. has been actively making R&D and facility investments as it inaugurated a new, state-of-the-art plant with international standard cGMP levels in Ochang, North Chungcheong Province in May 2005.
AMICABLE LABOR-MANAGEMENT TIES. Yuhan management and labor have been built up a solid foundation to gain conciliation and trust from each other by sharing an understanding of "riding the same boat together."No labor disputes have taken place for the past 80 years since its founding. Both sides have maintained equal relations and have a firm belief in promoting co-prosperity. Labor has been discussing and sharing the pending issues through such dialogue channels as quarterly performance reports, business plan deliberation, and labor-management joint sessions to solidify a firm foundation based on reliability.
SOCIAL RESPONSIBILITY. Yuhan has been contributed to the development of the national economy by achieving a high sales growth without falling into the red for the past 80 years since its founding and paying for taxes honestly, conducting fair, healthy transactions and operating plants without industrial accidents. In particular, the company has been praised for spearheading corporate social responsibility activities. Yuhan ranked 42nd in the 2003 list of corporations with social responsibility announced by the Financial Times.
VISION FOR ANOTHER 80 YEARS. Yuhan is striving to perform its corporate social responsibility based on integrity, honesty, challenge and creativity and keep on prospering for another 80 years with the goal of achieving its corporate vision: evolving an integrated healthcare corporation committed to improving the quality of lives.
Yuhan Corp. President Cha Jung-keon said, "I have a firm belief that companies can grow into a good, respected ones when all members build up confidence under the "Win-wind"strategies and 'communally destined"relationships."Yuhan President Cha was presented with the Order of Industrial Service, Silver Tower during the 34th Commerce-Industry Day anniversary on March 21 in recognition of the development of a gastrointestinal ulcer treatment medicine, Korea's first licensed new pharmaceutical.
Cha has been credited with having inherited and evolved "management based on confidence"and building up reliability from customers, employees and society.
Yuhan President Cha listens to the field voices of employees and sound out inside and outside views. He also focuses on cultivating gifted manpower through such steps as self-development programs. nw

(from left photo) Labor-management joint training session; company athletic meeting; and Yuhan Corp. President Cha Jung-keon